Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 5/2018

19.09.2018 | HIV and Technology (J Simoni and K Ronen, Section Editor)

Actionable Adherence Monitoring: Technological Methods to Monitor and Support Adherence to Antiretroviral Therapy

verfasst von: Kate M. Bell, Jessica E. Haberer

Erschienen in: Current HIV/AIDS Reports | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Current digital technologies are being used for “actionable adherence monitoring”; that is, technologies that can be used to identify episodes of non-adherence to ART in a timely manner such that tailored interventions based on adherence data can be provided when and where they are needed most.

Recent Findings

Current digital communication technologies used to monitor ART adherence include electronic adherence monitors (EAMs), digital ingestion monitors, cellular phones, and electronic pharmacy refill tracking systems.

Summary

Currently available real-time adherence monitoring approaches based on cellular technology allow for the delivery of interventions precisely when and where they are needed. Such technology can potentially enable significant efficiency of care delivery and impact on adherence and associated clinical outcomes. Standard digital advances, such as automated reminders in EAM and electronic pharmacy records, may also achieve improvements with relatively lower cost and easier implementation. Future research is needed to improve the functionality of these approaches, with attention paid to system-level issues through implementation science, as well as acceptability and ethical considerations at the individual level.
Literatur
1.
2.
UNAIDS. 90–90-90: An ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland: The Joint United Nations Programme on HIV/AIDS; 2014.
3.
Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376(9734):49–62.CrossRef
4.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRef
5.
• Haberer JE, Musinguzi N, Boum Y II, Siedner MJ, Mocello AR, Hunt PW, et al. Duration of antiretroviral therapy adherence interruption is associated with risk of virologic rebound as determined by real-time adherence monitoring in rural Uganda. J Acquir Immune Defic Syndr. 2015;70(4):386–92. This article is the first demonstration of HIV RNA rebound during adherence interruptions objectively measured in real time.CrossRef
6.
Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–23.CrossRef
7.
Info, A, Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2017.
8.
Bangsberg DR, Haberer JE. Lifetime HIV antiretroviral therapy adherence intervention: timing is everything: comment on “managed problem solving for antiretroviral therapy adherence”. JAMA Intern Med. 2013;173(4):306–7.CrossRef
9.
Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–45.CrossRef
10.
Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Bärnighausen T. Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS. 2014;28(Suppl 2):S187–204.CrossRef
11.
Haberer JE. Actionable adherence monitoring to optimise intervention. Lancet HIV. 2017;4(1):e5–6.CrossRef
12.
Vrijens B, de Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.CrossRef
13.
• Gallagher B, Munter P, Moise N, Lin JJ, Kronish IM. Are two commonly used self-report questionnaires useful for identifying antihypertensive medication nonadherence? J Hypertens. 2015;33:1108–13. Other tools, including electronic measurement, may be needed to guide titration of antihypertensive medications among patients with uncontrolled hypertension. CrossRef
14.
Genberg BL, Wilson IB, Bangsberg DR, Arnsten J, Goggin K, Remien RH, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26(11):1415–23.CrossRef
15.
Demonceau J, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs. 2013;73(6):545–62.CrossRef
16.
Vrijens B, Urquhart J, White D. Electronically monitored dosing histories can be used to develop a medication-taking habit and manage patient adherence. Expert Rev Clin Pharmacol. 2014;7(5):633–44.CrossRef
17.
18.
19.
• Jongbloed K, Parmar S, van der Kop M, Spittal PM, Lester RT. Recent evidence for emerging digital technologies to support global HIV engagement in care. Curr HIV/AIDS Rep. 2015;12(4):451–61. Technologies for health provide emerging and proven solutions to support achievement of the United Nations targets for the generalized HIV-affected population.CrossRef
20.
• Van der Elst EM, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72. Analyses identified three themes: (i) acceptability of PrEP was high, i.e. side effects were experienced early in the study but diminished over time, however characteristics of pills could improve comfort and use; (ii) social impacts such as stigma, rumors, and relationship difficulties due to being perceived as HIV positive were prevalent; (iii) adherence was challenged by complexities of daily life, in particular post-coital dosing adherence suffered from alcohol use around time of sex, mobile populations, and transactional sex work.CrossRef
21.
de Sumari-de Boer IM, van den Boogaard J, Ngowi KM, Semvua HH, Kiwango KW, Aarnoutse RE, et al. Feasibility of real time medication monitoring among HIV infected and TB patients in a resource-limited setting. AIDS Behav. 2016;20(5):1097–107.CrossRef
22.
• Sabin L, et al. Improving adherence to antiretroviral therapy with triggered real-time text message reminders: the China Adherence Through Technology Study. J Acquir Immune Defic Syndr. 2015;69(5):551–9. Real-time reminders significantly improved ART adherence in some populations.CrossRef
23.
• Evans D, Berhanu R, Moyo F, Nguweneza A, Long L, Fox MP. Can short-term use of electronic patient adherence monitoring devices improve adherence in patients failing second-line antiretroviral therapy? Evidence from a pilot study in Johannesburg. South Africa AIDS Behav. 2016;20(11):2717–28. In patients with an elevated viral load on second-line ART electronic adherence monitoring was associated with a modest, but not significant, improvement in viral suppression.CrossRef
24.
• Atukunda EC, Musiimenta A, Musinguzi N, Wyatt MA, Ashaba J, Ware NC, et al. Understanding patterns of social support and their relationship to an ART adherence intervention among adults in rural southwestern Uganda. AIDS Behav. 2017;21(2):428–40. Effective social support appeared subject to social supporters' food security, economic stability and a well-functioning social network dependent on trust and supportive disclosure.CrossRef
25.
Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS One. 2012;7(5):e36737.CrossRef
26.
Haberer, J., Does the monitoring of medication packaging tell us what we need to know about TB treatment adherence. 2017, UNION.
27.
• Mbuagbaw L, van der Kop ML, Lester RT, Thirumurthy H, Pop-Eleches C, Ye C, et al. Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials. BMJ Open. 2013;3(12):e003950. Text messaging has a significant effect on adherence to ART, and this effect is influenced by level of education, gender, timing (weekly vs daily) and interactivity. We recommend the use of interactive weekly text messaging to improve adherence to ART, which is most effective in those with at least a primary level of education.CrossRef
28.
• Orrell C, Cohen K, Mauff K, Bangsberg DR, Maartens G, Wood R. A randomized controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;70(5):495–502. Text message reminders linked to late doses detected by real-time adherence monitoring reduced the number of prolonged TIs, but did not significantly improve adherence or viral suppression.CrossRef
29.
• Haberer J, et al. Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring. AIDS. 2017;31:169–71. Real-time EAM is a promising approach for improving adherence.CrossRef
30.
• Liu, X., et al., Usability of a Medication Event Reminder Monitor System (MERM) by Providers and Patients to Improve Adherence in the Management of Tuberculosis. Int J Environ Res Public Health. 2017;14(10). Electronic monitoring is becoming the standard of care for drug-susceptible TB patients in China and scaled implementations in several other countries with high TB burden have begun.CrossRef
31.
• Hafezi H, Robertson TL, Moon GD, Au-Yeung KY, Zdeblick MJ, Savage GM. An ingestible sensor for measuring medication adherence. IEEE Trans Biomed Eng. 2015;62(1):99–109. Aggregate results from multiple clinical trials involving 412 patients and 5656 days of system usage are presented to demonstrate the device's reliability and performance as part of an overall digital health feedback system.CrossRef
32.
Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, DiCarlo L, et al. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One. 2013;8(1):e53373.CrossRef
33.
Kane JM. Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success. J Clin Psychiatry. 2013;74(9):e18.CrossRef
34.
• Browne SH, Behzadi Y, Littlewort G. Let visuals tell the story: medication adherence in patients with type II diabetes captured by a novel ingestion sensor platform. JMIR Mhealth Uhealth. 2015;3(4):e108. Visualizations integrating medication ingestion and physiological data from the DHFS over varying time intervals captured detailed individual longitudinal patterns of medication adherence and self-management in the natural setting.CrossRef
35.
36.
Encyclopedia of Behavioral Medicine. 2013, New York: Springer Science+Business Media.
37.
• DiCarlo LA, Weinstein RL, Morimoto CB, Savage GM, Moon GL, Au-Yeung K, et al. Patient-centered home care using digital medicine and telemetric data for hypertension: feasibility and acceptability of objective ambulatory assessment. J Clin Hypertens (Greenwich). 2016;18(9):901–6. Ambulatory evaluation of medication adherence and habits of daily living appear to be feasible and acceptable using DM and passive acquisition of telemetric data.CrossRef
38.
Belluck, P. First digital pill approved to worries about biomedical ‘big brother’. New York Times, 2017.
39.
40.
Swendeman D, Jana S, Ray P, Mindry D, Das M, Bhakta B. Development and pilot testing of daily interactive voice response (IVR) calls to support antiretroviral adherence in India: a mixed-methods pilot study. AIDS Behav. 2015;19(Suppl 2):142–55.CrossRef
41.
Ramanathan N, Swendeman D, Comulada WS, Estrin D, Rotheram-Borus MJ. Identifying preferences for mobile health applications for self-monitoring and self-management: focus group findings from HIV-positive persons and young mothers. Int J Med Inform. 2013;82(4):e38–46.CrossRef
42.
Swendeman D, Ramanathan N, Baetscher L, Medich M, Scheffler A, Comulada WS, et al. Smartphone self-monitoring to support self-management among people living with HIV: perceived benefits and theory of change from a mixed-methods randomized pilot study. J Acquir Immune Defic Syndr. 2015;69(Suppl 1):S80–91.CrossRef
43.
Haberer JE, Kiwanuka J, Nansera D, Muzoora C, Hunt PW, So J, et al. Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27(13):2166–8.CrossRef
44.
Curran K, Mugo NR, Kurth A, Ngure K, Heffron R, Donnell D, et al. Daily short message service surveys to measure sexual behavior and pre-exposure prophylaxis use among Kenyan men and women. AIDS Behav. 2013;17(9):2977–85.CrossRef
45.
Olds PK, Kiwanuka JP, Ware NC, Tsai AC, Haberer JE. Explaining antiretroviral therapy adherence success among HIV-infected children in rural Uganda: a qualitative study. AIDS Behav. 2015;19(4):584–93.CrossRef
46.
Kenneth Ngure, J.H., J Baeten, R Heffron, E Katabira, N Mugo, B Burns, B Nankya, G Kimemia, T Muwonge, “It was easy”: a qualitative analysis of participant experiences responding to short message service (SMS) surveys on pre-exposure prophylaxis (PrEP) adherence and sexual behavior in East Africa. , in 11th International Conference on HIV Treatment and Prevention Adherence. 2016: Ft. Lauderdale, FL.
47.
Ngwatu BK, et al., The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J, 2018;51(1).CrossRef
48.
Sangeda RZ, Mosha F, Prosperi M, Aboud S, Vercauteren J, Camacho RJ, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health. 2014;14:1035.CrossRef
49.
Puttkammer N, Zeliadt S, Balan JG, Baseman J, Destiné R, Domerçant JW, et al. Development of an electronic medical record based alert for risk of HIV treatment failure in a low-resource setting. PLoS One. 2014;9(11):e112261.CrossRef
50.
• Haberer J, et al., Improving antiretorivral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. J Int AIDS Soc. 2017;20(21371). The evidence base is promising for currently available, effective, and scalable ART adherence interventions for resource-limited settings.
51.
Haberer JE, Robbins GK, Ybarra M, Monk A, Ragland K, Weiser SD, et al. Real-time electronic adherence monitoring is feasible, comparable to unannounced pill counts, and acceptable. AIDS Behav. 2012;16(2):375–82.CrossRef
52.
Hill S, Kavookjian J. Motivational interviewing as a behavioral intervention to increase HAART adherence in patients who are HIV-positive: a systematic review of the literature. AIDS Care. 2012;24(5):583–92.CrossRef
53.
Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS Med. 2015;12(9):e1001876.CrossRef
54.
• Ware NC, Pisarski EE, Tam M, Wyatt MA, Atukunda E, Musiimenta A, et al. The meanings in the messages: how SMS reminders and real-time adherence monitoring improve antiretroviral therapy adherence in rural Uganda. AIDS. 2016;30(8):1287–94. Although serving as reminders, SMS messages and real-time adherence monitoring also had larger emotional and moral meanings for participants that they felt improved their adherence.CrossRef
55.
Mayo, E. Social problems for an industrial civilization. 1945. 2018].
56.
Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e88166.CrossRef
57.
• Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. 2016;176(3):340–9. Mobile phone text messaging approximately doubles the odds of medication adherence.CrossRef
58.
Kalichman SC, Amaral CM, Stearns H, White D, Flanagan J, Pope H, et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med. 2007;22(7):1003–6.CrossRef
59.
Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284–97.CrossRef
60.
Haberer JE, Ngure K, Muwonge T, Mugo N, Katabira E, Heffron R, et al. Brief report: context matters: PrEP adherence is associated with sexual behavior among HIV serodiscordant couples in East Africa. J Acquir Immune Defic Syndr. 2017;76(5):488–92.CrossRef
61.
• Himelhoch S, Kreyenbuhl J, Palmer-Bacon J, Chu M, Brown C, Potts W. Pilot feasibility study of Heart2HAART: a smartphone application to assist with adherence among substance users living with HIV. AIDS Care. 2017;29(7):898–904. Heart2HAART was feasible to use during a three-month pilot trial. Future studies may evaluate a more tailored approach, with more robust contingency management.CrossRef
62.
WHO, Meeting Report on Assessment of World Health Organization HIV Drug Resistance Early Warning Indicators: Report of the Early Warning Indicator Advisory Panel Meeting. 2011, World Health Organization: Geneva, Switzerland.
63.
Orrell C, Dipenaar R, Killa N, Tassie JM, Harries AD, Wood R. Simplifying HIV cohort monitoring—pharmacy stock records minimize resources necessary to determine retention in care. JAIDS J Acquir Immune Defic Syndr. 2013;62(3):e106–8.CrossRef
64.
Douglas GP, et al., Using touchscreen electronic medical record systems to support and monitor national scale-up of antiretroviral therapy in Malawi. PLoS Med. 2010;7(8).CrossRef
65.
Tweya H, Feldacker C, Ben-Smith A, Harries AD, Komatsu R, Jahn A, et al. Simplifying ART cohort monitoring: can pharmacy stocks provide accurate estimates of patients retained on antiretroviral therapy in Malawi? BMC Health Serv Res. 2012;12:210.CrossRef
66.
67.
Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AIM, Wensing AMJ. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155–66.CrossRef
68.
• Campbell JI, et al. Ethical questions in medical electronic adherence monitoring. J Gen Intern Med. 2016;31(3):338–42. The unique benefits as well as the potential ethical challenges that electronic adherence monitoring generates. These challenges surround autonomy, privacy and confidentiality, trust, and ancillary care obligations.CrossRef
69.
• Richardson HS, Eyal N, Campbell JI, Haberer JE. When ancillary care clashes with study aims. N Engl J Med. 2017;377(13):1213–5. Providing ancillary care is sometimes obligatory in medical and health care studies. Its provision may, however, collide with achievement of a study’s aims.CrossRef
70.
• Chai PR, Carreiro S, Innes BJ, Rosen RK, O'Cleirigh C, Mayer KH, et al. Digital pills to measure opioid ingestion patterns in emergency department patients with acute fracture pain: a pilot study. J Med Internet Res. 2017;19(1):e19. Deploying digital pills is possible through the ED with a short instructional course. Patients who used the digital pill accepted the technology.CrossRef
Metadaten
Titel
Actionable Adherence Monitoring: Technological Methods to Monitor and Support Adherence to Antiretroviral Therapy
verfasst von
Kate M. Bell
Jessica E. Haberer
Publikationsdatum
19.09.2018
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 5/2018
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-018-0413-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise